Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06654089 · ClinicalTrials.gov registry record · Phase 4
A Study Evaluating Quality of Life Parameters Following Use of Emergen-C
A Phase 4 study, sponsored by HALEON.
- Completed
- Registry status
- Phase 4
- Development phase
- 299
- Enrollment target
NCT06654089: Completed Phase 4 study, sponsored by HALEON.
NCT06654089 is a Phase 4 study that has completed, run by HALEON. The registered enrollment target is 299 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (42% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06654089, a Phase 4 study, has completed, sponsored by HALEON.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 299 participants
- Enrollment target
Study Summary
The purpose of this study is to determine how Emergen-C use can improve quality of life (QoL) in a real-world setting to help consumers and healthcare professionals understand the benefits of taking Emergen-C on a routine or daily basis.
Primary Outcome
The MFI was a 20-item scale designed to evaluate five dimensions of fatigue: general fatigue, physical fatigue, reduced motivation, reduced activity, and mental fatigue. General fatigue domain had 4 items. Participants answered how they felt about each item, on a scale of 1 (yes, that is true) to 5 (no, that is not true). Positively phrased items were reversely scored and negatively phrased items were scored at face value. The total domain score was calculated by summation of the scores of indiv
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Emergen-C Core Super Orange Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 299 participants |
| Start Date | 2024-10-30 |
| Est. Completion | 2025-02-24 |
| Phase | Phase 4 |
What the finished NCT06654089 record still lists
NCT06654089 is an interventional study that assigns participants to a tested intervention. The registered 299 participants enrollment target is mid-sized for trials with a published cap, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (42% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06654089 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06654089 about?
NCT06654089 is a clinical study titled "A Study Evaluating Quality of Life Parameters Following Use of Emergen-C". The purpose of this study is to determine how Emergen-C use can improve quality of life (QoL) in a real-world setting to help consumers and healthcare professionals understand the benefits of taking Emergen-C on a routine or daily basis.
What is the current status of trial NCT06654089?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 299 participants. The study started on 2024-10-30. Estimated completion is 2025-02-24.
What interventions are being tested in trial NCT06654089?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Emergen-C Core Super Orange Powder (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT06654089?
This trial is sponsored by HALEON, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06654089's enrollment target sits among peer trials
299 292nd of 2000 higher than 1,709 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00353483 · 300 participants
Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells
- NCT00588185 · 300 participants · NA
[18F]-Fluoro-2-Deoxy-D-Glucose and -[18F] Dihydro-Testosterone Pet Imaging in Patients With Progressive Prostate Cancer
- NCT00682032 · 300 participants · NA
The Effect of Beta-glucan in Non-Small Cell Lung Cancer
- NCT00870064 · 300 participants · NA
The Treatment of Type I Open Fractures in Pediatrics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI